Newsroom

November 22, 2019 2019-11-22

TAKHZYRO^® (lanadelumab injection) receives positive recommendation from CADTH’s Canadian Drug Expert Committee (CDEC) for the routine prevention of hereditary angioedema (HAE) attacks

July 10, 2019 2019-07-10 Health Canada has authorized VYVANSE® (lisdexamfetamine dimesylate), the first and only, chewable tablet for the treatment of attention deficit/hyperactivity disorder (ADHD)¹

June 13, 2019 2019-06-13 Pedalling in support of rare disease research

March 11, 2019 2019-03-11 Takeda Canada announces positive results for ENTYVIO® (vedolizumab) vs. Humira® (adalimumab) in first IBD study to compare biological agents head-to-head

March 1, 2019 2019-03-01 One in 12 Canadians are affected by a rare disease. Are you one of them? Takeda Canada commemorates Rare Disease Day with the launch of video patient stories

Recent News Releases